Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant | Breast Cancer Research | Full Text
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
Overall survival between matched MONARCH 1 and real-world chemotherapy... | Download Scientific Diagram
Kaplan-Meier curves for progression-free survival in the premenopausal... | Download Scientific Diagram
MONARCH 3: Overall Survival Results of Abemaciclib Plus Nonsteroidal AI for HR+/HER2− Advanced Breast Cancer | PracticeUpdate
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant | Breast Cancer Research | Full Text
Carlo Palmieri on X: "MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison
![PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b7bbed1ac97b7cd7e1722645a4773fc21e58df3/3-Figure1-1.png "PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar")
PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library
ESMO 2022: MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Carlo Palmieri on X: "MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison
Archive | ESMO
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/5-Figure4-1.png "PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar")
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
Verzenio® + Fulvestrant | Efficacy | Verzenio (abemaciclib)
Carlo Palmieri (@cancermedic) / X
Abemaciclib plus aromatase inhibitor in advanced breast cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Journal of Clinical Oncology on X: "MONARCH 3 trial: Abemaciclib as initial therapy for advanced breast cancer https://t.co/YlEshSmVC7 #bcsm https://t.co/3hGY4XRWHd" / X
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
